WO2024036106A1 - Complémentation de microglie embryonnaire pour manipulation in vivo de microglie et production d'un modèle animal non humain pour la validation de la fonction génique et le criblage thérapeutique - Google Patents
Complémentation de microglie embryonnaire pour manipulation in vivo de microglie et production d'un modèle animal non humain pour la validation de la fonction génique et le criblage thérapeutique Download PDFInfo
- Publication number
- WO2024036106A1 WO2024036106A1 PCT/US2023/071778 US2023071778W WO2024036106A1 WO 2024036106 A1 WO2024036106 A1 WO 2024036106A1 US 2023071778 W US2023071778 W US 2023071778W WO 2024036106 A1 WO2024036106 A1 WO 2024036106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microglia
- human animal
- gene
- chimeric
- cells
- Prior art date
Links
- 210000000274 microglia Anatomy 0.000 title claims abstract description 189
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 61
- 238000012216 screening Methods 0.000 title claims abstract description 20
- 210000001161 mammalian embryo Anatomy 0.000 title claims description 89
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 238000010171 animal model Methods 0.000 title abstract description 10
- 230000001225 therapeutic effect Effects 0.000 title abstract description 10
- 238000010200 validation analysis Methods 0.000 title abstract description 8
- 238000001727 in vivo Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 189
- 241001465754 Metazoa Species 0.000 claims abstract description 52
- 230000035772 mutation Effects 0.000 claims abstract description 51
- 210000002459 blastocyst Anatomy 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 127
- 210000000130 stem cell Anatomy 0.000 claims description 108
- 239000003795 chemical substances by application Substances 0.000 claims description 65
- 108091011896 CSF1 Proteins 0.000 claims description 61
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 61
- 101150090155 R gene Proteins 0.000 claims description 55
- 108700026215 vpr Genes Proteins 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 53
- 108020005004 Guide RNA Proteins 0.000 claims description 47
- 108091033409 CRISPR Proteins 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 40
- 101710163270 Nuclease Proteins 0.000 claims description 36
- -1 S0D1 Proteins 0.000 claims description 28
- 210000001082 somatic cell Anatomy 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 24
- 108700028369 Alleles Proteins 0.000 claims description 21
- 230000004913 activation Effects 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 18
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 15
- 102100033272 Macrophage receptor MARCO Human genes 0.000 claims description 14
- 101710089357 Macrophage receptor MARCO Proteins 0.000 claims description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 14
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 13
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 claims description 13
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 13
- 230000028327 secretion Effects 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 102000014150 Interferons Human genes 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 102000015696 Interleukins Human genes 0.000 claims description 12
- 108010063738 Interleukins Proteins 0.000 claims description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 12
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 12
- 210000004504 adult stem cell Anatomy 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 12
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 12
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 11
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 claims description 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 11
- 210000003169 central nervous system Anatomy 0.000 claims description 11
- 230000000946 synaptic effect Effects 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 11
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 9
- 102000019034 Chemokines Human genes 0.000 claims description 9
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 9
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 claims description 9
- 101000956320 Homo sapiens Membrane-spanning 4-domains subfamily A member 6A Proteins 0.000 claims description 9
- 101000956324 Homo sapiens Membrane-spanning 4-domains subfamily A member 6E Proteins 0.000 claims description 9
- 101000929663 Homo sapiens Phospholipid-transporting ATPase ABCA7 Proteins 0.000 claims description 9
- 101000956322 Homo sapiens Putative membrane-spanning 4-domains subfamily A member 4E Proteins 0.000 claims description 9
- 102100038556 Membrane-spanning 4-domains subfamily A member 4A Human genes 0.000 claims description 9
- 102100038555 Membrane-spanning 4-domains subfamily A member 6A Human genes 0.000 claims description 9
- 102100038468 Membrane-spanning 4-domains subfamily A member 6E Human genes 0.000 claims description 9
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 9
- 206010057249 Phagocytosis Diseases 0.000 claims description 9
- 102100036620 Phospholipid-transporting ATPase ABCA7 Human genes 0.000 claims description 9
- 102100038469 Putative membrane-spanning 4-domains subfamily A member 4E Human genes 0.000 claims description 9
- 241000283984 Rodentia Species 0.000 claims description 9
- 238000010459 TALEN Methods 0.000 claims description 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 230000003959 neuroinflammation Effects 0.000 claims description 9
- 230000008782 phagocytosis Effects 0.000 claims description 9
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- 108090000174 Interleukin-10 Proteins 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 8
- 230000001640 apoptogenic effect Effects 0.000 claims description 8
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 8
- 230000037433 frameshift Effects 0.000 claims description 8
- 102100027209 CD2-associated protein Human genes 0.000 claims description 7
- 102100030886 Complement receptor type 1 Human genes 0.000 claims description 7
- 101000914499 Homo sapiens CD2-associated protein Proteins 0.000 claims description 7
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 7
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 7
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 claims description 7
- 101000613577 Homo sapiens Paired box protein Pax-2 Proteins 0.000 claims description 7
- 101001027324 Homo sapiens Progranulin Proteins 0.000 claims description 7
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 7
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 7
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 7
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 7
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 7
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims description 7
- 102100040852 Paired box protein Pax-2 Human genes 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 102100037632 Progranulin Human genes 0.000 claims description 7
- 238000003559 RNA-seq method Methods 0.000 claims description 7
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 7
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 238000013138 pruning Methods 0.000 claims description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 7
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 7
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 6
- 101000823089 Equus caballus Alpha-1-antiproteinase 1 Proteins 0.000 claims description 6
- 102100020997 Fractalkine Human genes 0.000 claims description 6
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 6
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 6
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 6
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 6
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 claims description 6
- 102000013691 Interleukin-17 Human genes 0.000 claims description 6
- 108010002616 Interleukin-5 Proteins 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 6
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 6
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 102100027654 Transcription factor PU.1 Human genes 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 6
- 229930195712 glutamate Natural products 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000010208 microarray analysis Methods 0.000 claims description 6
- 210000000653 nervous system Anatomy 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 108700004991 Cas12a Proteins 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010083674 Myelin Proteins Proteins 0.000 claims description 4
- 102000006386 Myelin Proteins Human genes 0.000 claims description 4
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 210000000472 morula Anatomy 0.000 claims description 4
- 210000005012 myelin Anatomy 0.000 claims description 4
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 230000008995 epigenetic change Effects 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 2
- 102000018779 Replication Protein C Human genes 0.000 claims 1
- 108010027647 Replication Protein C Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 56
- 125000003729 nucleotide group Chemical group 0.000 description 55
- 208000002193 Pain Diseases 0.000 description 49
- 238000012360 testing method Methods 0.000 description 47
- 230000036407 pain Effects 0.000 description 46
- 208000004454 Hyperalgesia Diseases 0.000 description 39
- 201000010099 disease Diseases 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 108091033319 polynucleotide Proteins 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 150000007523 nucleic acids Chemical group 0.000 description 24
- 230000000295 complement effect Effects 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 230000008672 reprogramming Effects 0.000 description 20
- 239000013598 vector Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 208000024827 Alzheimer disease Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 201000011240 Frontotemporal dementia Diseases 0.000 description 8
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 8
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 241000271566 Aves Species 0.000 description 7
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 206010053552 allodynia Diseases 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 208000021320 Nasu-Hakola disease Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000020341 sensory perception of pain Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 208000007089 vaccinia Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 4
- 241000700663 Avipoxvirus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 238000010446 CRISPR interference Methods 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000710960 Sindbis virus Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 108091028113 Trans-activating crRNA Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000243791 Angiostrongylus Species 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 241000228405 Blastomyces dermatitidis Species 0.000 description 3
- 241000589969 Borreliella burgdorferi Species 0.000 description 3
- 241000589562 Brucella Species 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 3
- 241000223205 Coccidioides immitis Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000244160 Echinococcus Species 0.000 description 3
- 241001466953 Echovirus Species 0.000 description 3
- 241000605314 Ehrlichia Species 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241000224432 Entamoeba histolytica Species 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241001276383 Gnathostoma spinigerum Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000893570 Hendra henipavirus Species 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000228404 Histoplasma capsulatum Species 0.000 description 3
- 241001272567 Hominoidea Species 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000701027 Human herpesvirus 6 Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000701460 JC polyomavirus Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000589902 Leptospira Species 0.000 description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241000711386 Mumps virus Species 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 241000526636 Nipah henipavirus Species 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 241000187654 Nocardia Species 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 241000606701 Rickettsia Species 0.000 description 3
- 241000710799 Rubella virus Species 0.000 description 3
- 241000242678 Schistosoma Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001149963 Sporothrix schenckii Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 241000223997 Toxoplasma gondii Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 241000589884 Treponema pallidum Species 0.000 description 3
- 241000031115 Trichobilharzia regenti Species 0.000 description 3
- 241000223104 Trypanosoma Species 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- 210000001642 activated microglia Anatomy 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 208000029560 autism spectrum disease Diseases 0.000 description 3
- 210000000467 autonomic pathway Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006720 chronic neuroinflammation Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229940007078 entamoeba histolytica Drugs 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000002025 microglial effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 108091008700 nociceptors Proteins 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241001261858 Alsodes Species 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 241000251556 Chordata Species 0.000 description 2
- 102100028188 Cystatin-F Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000000802 Galectin 3 Human genes 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 241000272496 Galliformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100033636 Histone H3.2 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000749325 Homo sapiens C-type lectin domain family 7 member A Proteins 0.000 description 2
- 101000916688 Homo sapiens Cystatin-F Proteins 0.000 description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000276569 Oryzias latipes Species 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710174326 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101710174937 Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008533 pain sensitivity Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100123845 Aphanizomenon flos-aquae (strain 2012/KM1/D3) hepT gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000616876 Belliella baltica Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 108050002829 DNA (cytosine-5)-methyltransferase 3A Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102000029812 HNH nuclease Human genes 0.000 description 1
- 108060003760 HNH nuclease Proteins 0.000 description 1
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 1
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 241001647888 Psychroflexus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 241001606419 Spiroplasma syrphidicola Species 0.000 description 1
- 241000203029 Spiroplasma taiwanense Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004590 drinking behavior Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- IIPNDONTVPDUFZ-UHFFFAOYSA-N ethyl 2-methyl-1-oxido-3,4-dihydropyrrol-1-ium-2-carboxylate Chemical compound CCOC(=O)C1(C)CCC=[N+]1[O-] IIPNDONTVPDUFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000019637 foraging behavior Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007277 glial cell activation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 208000021731 hypoalgesia Diseases 0.000 description 1
- 230000036032 hypoalgesia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002902 organometallic compounds Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
Definitions
- a non-human animal comprising chimeric microglia and methods of performing blastocyst microglia complementation to produce such a non-human chimeric animal are disclosed.
- the disclosed methods can be used to produce a non-human animal model carrying microglia mutations of interest for gene validation and therapeutic screening.
- a method of producing a non-human animal comprising chimeric microglia comprising: a) genetically modifying a non-human animal host embryo by deleting or inactivating a CSF1 R gene; b) transplanting a stem cell comprising a functional CSF1 R gene into the non-human animal host embryo to produce a chimeric non-human animal host embryo; and c) producing a non-human animal from the chimeric non-human animal host embryo, wherein differentiation of the stem cell generates the chimeric microglia in the nervous system of the non-human animal.
- the non-human animal host embryo is genetically modified to delete or inactivate the CSF1 R gene at the single-celled zygote stage.
- the stem cell is transplanted into the non-human host animal embryo at the blastocyst stage.
- the stem cell comprises a mutation of interest.
- the mutation of interest is linked to a microglia disorder.
- the non-human animal is a mammal. In some embodiments, the mammal is a rodent.
- the stem cells are embryonic stem cells, adult stem cells, or induced pluripotent stem cells.
- the method further comprises performing transcriptomic profiling of the microglia.
- a non-human animal comprising chimeric microglia produced by a method, described herein, is provided.
- a non-human animal host embryo comprising: a genetically modified genome comprising a knockout of a CSF1 R gene; and transplanted stem cells having a wild-type CSF1 R gene, wherein a non-human animal can be produced from the chimeric non-human animal host embryo, wherein differentiation of the transplanted stem cells generates chimeric microglia in the nervous system of the non-human animal during development.
- a method of screening a candidate agent comprising: administering the candidate agent to a non-human animal comprising chimeric microglia, produced by a method, described herein; and detecting an effect of the candidate agent on morphology, gene expression, or activity of the chimeric microglia.
- detecting morphology comprises detecting ramified, reactive, activated, amoeboid, or rod-like morphology.
- measuring activity of the chimeric microglia comprises measuring secretion of cytokines, chemokines, NO, glucocorticoids, glutamate, or proteases, phagocytosis, synaptic pruning, or production of reactive oxygen species (ROS).
- ROS reactive oxygen species
- measuring secretion comprises detecting cytokines such as interleukin (IL)-4, IL-5, IL-10, IL-13, IL-10, IL-6, IL-12, IL-17, IL-18, IL-23, transforming growth factor (TGF)-0, tumor necrosis factor (TNF)-a, or interferon (IFN)-y, or chemokines such as CCL2, CX3CL1 , or CXCL10, or any combination thereof.
- cytokines such as interleukin (IL)-4, IL-5, IL-10, IL-13, IL-10, IL-6, IL-12, IL-17, IL-18, IL-23, transforming growth factor (TGF)-0, tumor necrosis factor (TNF)-a, or interferon (IFN)-y
- TGF tumor necrosis factor
- IFN interferon
- measuring gene expression comprises performing microarray analysis, RNA sequencing, or quantitative polymerase chain reaction.
- measuring gene expression comprises detecting expression of a microglia activation marker.
- the activation marker is IBA-1 , TLR4, CD14, CD16 CD32, CD86, macrophage receptor with collagenous structure (MARCO), or major histocompatibility complex II.
- the method further comprises detecting neuroinflammation in the non-human animal.
- method further comprises measuring the ability of the chimeric microglia to remove foreign material, toxins, pathogens, damaged cells, apoptotic cells, synaptic remnants, myelin debris, DNA fragments, neurofibrillary tangles, or plaques in the central nervous system of the non-human animal.
- the candidate agent is administered locally to the chimeric microglia.
- the genome of the non-human animal comprises a mutation linked to a microglia disorder.
- the mutation is in a gene selected from the group consisting of TREM2, TYROBP, CR1, SPI1, MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7, CD33, INPP5D, CD2AP, SOD1, GRN, PAX2, LRRK2, RIPK1, FMR1, DNMT3A, BIN1, and TET2.
- a method of transplanting microglia into a mammalian recipient subject comprising transplanting the chimeric microglia from a non-human animal, produced by a method, described herein to the mammalian recipient subject.
- the stem cells are human stem cells.
- the mammalian recipient subject is human.
- a non-human animal host embryo, described herein, in the manufacture of chimeric microglia is provided.
- at least 90% of the cells in the chimeric microglia are produced from the stem cells.
- the stem cells are mammalian stem cells.
- the mammalian stem cells are human stem cells.
- FIG. 1 Current research limitations for studying microglia.
- FIG. 2 Microglia replacement models (Xu et al., 2020, Cell Reports 32, 108041 ).
- FIG. 3 Current microglia replacement model limitations.
- FIG. 4 Blastocyst complementation of microglia.
- FIG. 5 Flow cytometry analysis shows adult chimera have high microglia chimerism in the spinal cord.
- a non-human animal comprising chimeric microglia and methods of performing blastocyst microglia complementation to produce such a non-human chimeric animal are disclosed.
- the disclosed methods can be used to produce a non-human animal model carrying microglia mutations of interest for gene validation and therapeutic screening.
- a cell includes a plurality of such cells and reference to “the embryo” includes reference to one or more embryos and equivalents thereof, e.g., blastocysts or morulas, known to those skilled in the art, and so forth.
- stem cell refers to a cell that retains the ability to renew itself through mitotic cell division and that can differentiate into a diverse range of specialized cell types.
- Mammalian stem cells can be divided into three broad categories: embryonic stem cells, which are derived from blastocysts, adult stem cells, which are found in adult tissues, and cord blood stem cells, which are found in the umbilical cord. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body by replenishing specialized cells. Totipotent stem cells are produced from the fusion of an egg and sperm cell.
- Cells produced by the first few divisions of the fertilized egg are also totipotent. These cells can differentiate into embryonic and extraembryo nic cell types. Pluripotent stem cells are the descendants of totipotent cells and can differentiate into cells derived from any of the three germ layers. Multipotent stem cells can produce only cells of a closely related family of cells (e.g., hematopoietic stem cells differentiate into red blood cells, white blood cells, platelets, etc.). Unipotent cells can produce only one cell type, but have the property of self-renewal, which distinguishes them from non-stem cells.
- Induced pluripotent stem cells are a type of pluripotent stem cell derived from adult cells that have been reprogrammed into an embryonic-like pluripotent state.
- Induced pluripotent stem cells can be derived, for example, from adult somatic cells such as peripheral blood mononuclear cells, fibroblasts, keratinocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells, adipose cells, leukocytes, hematopoietic stem cells, bone marrow cells, or hepatocytes.
- reprogramming factors refers to one or more, i.e., a cocktail, of biologically active factors that act on a cell to alter transcription, thereby reprogramming a cell to multipotency or to pluripotency.
- Reprogramming factors may be provided individually or as a single composition, that is, as a premixed composition, of reprogramming factors to the cells, e.g., somatic cells from an individual with a family history or genetic make-up of interest, such as a patient who has a neurological disorder or a neurodegenerative disease.
- the factors may be provided at the same molar ratio or at different molar ratios.
- the reprogramming factor is a transcription factor, including without limitation, Oct3/4; Sox2; Klf4; c-Myc; Nanog; and Lin-28.
- the somatic cells may include, without limitation, peripheral blood mononuclear cells, fibroblasts, keratinocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells, adipose cells, leukocytes, hematopoietic stem cells, bone marrow cells, or hepatocytes, etc., which are contacted with reprogramming factors, as defined above, in a combination and quantity sufficient to reprogram the cell to pluripotency.
- Reprogramming factors may be provided to the somatic cells individually or as a single composition, that is, as a premixed composition, of reprogramming factors. In some embodiments the reprogramming factors are provided as a plurality of coding sequences on a vector.
- container is meant a glass, plastic, or metal vessel that can provide an aseptic environment for culturing cells.
- animal is used herein to include all vertebrate animals, except humans.
- the term also includes animals at all stages of development, including embryonic, fetal, neonate, and adult stages.
- Animals may include any member of the subphylum Chordata, including, without limitation, non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; fish, including zebrafish and medaka; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
- transgenic animal is meant a non-human animal, usually a mammal, having a non- endogenous (i.e., heterologous or foreign) nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells).
- a heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal according to methods well known in the art.
- a “transgene” is meant to refer to such a heterologous nucleic acid, e.g., heterologous nucleic acid in the form of an expression construct (e.g., for the production of a "knock-in” transgenic animal) or a heterologous nucleic acid that upon insertion within or adjacent a target gene results in a decrease in target gene expression (e.g., for production of a "knock-out” transgenic animal).
- a DNA molecule is artificially introduced into the cells of an animal, a “transgenic animal” is produced.
- the DNA molecule is called a "transgene” and may contain one or many genes.
- subject any member of the subphylum Chordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; fish, including zebrafish and medaka; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
- chimeric refers to cells (e.g., microglia) from a different species than a host animal embryo or animal.
- transfection is used to refer to the uptake of foreign DNA or RNA by a cell.
- a cell has been "transfected” when exogenous DNA or RNA has been introduced inside the cell membrane.
- transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (2001 ) Molecular Cloning, a laboratory manual, 3rd edition, Cold Spring Harbor Laboratories, New York, Davis et al. (1995) Basic Methods in Molecular Biology, 2nd edition, McGraw-Hill, and Chu et al. (1981 ) Gene 13:197.
- a “CRISPR system” refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas") genes.
- one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system.
- one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
- a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
- Cas9 encompasses type II clustered regularly interspaced short palindromic repeats (CRISPR) system Cas9 endonucleases from any species, and also includes biologically active fragments, variants, analogs, and derivatives thereof that retain Cas9 endonuclease activity (i.e., catalyze site-directed cleavage of DNA to generate double-strand breaks).
- CRISPR type II clustered regularly interspaced short palindromic repeats
- a Cas9 endonuclease binds to and cleaves DNA at a site comprising a sequence complementary to its bound guide RNA (gRNA).
- a gRNA may comprise a sequence "complementary" to a target sequence (e.g., major or minor allele), capable of sufficient base-pairing to form a duplex (i.e., the gRNA hybridizes with the target sequence).
- the gRNA may comprise a sequence complementary to a PAM sequence, wherein the gRNA also hybridizes with the PAM sequence in a target DNA.
- a gRNA will bind to a substantially complementary sequence and not to unrelated sequences.
- a gRNA that "selectively binds" to a particular allele, such as a particular mutant allele e.g., allele comprising a substitution, insertion, or deletion) denotes a gRNA that binds preferentially to the particular target allele, but to a lesser extent to a wild-type allele or other sequences.
- a gRNA that selectively binds to a particular target DNA sequence will selectively direct binding of Cas9 to a substantially complementary sequence at the target site and not to unrelated sequences.
- donor polynucleotide refers to a polynucleotide that provides a sequence of an intended edit to be integrated into the genome at a target locus by homology directed repair (HDR).
- a "target site” or “target sequence” is the nucleic acid sequence recognized (i.e., sufficiently complementary for hybridization) by a guide RNA (gRNA) or a homology arm of a donor polynucleotide.
- gRNA guide RNA
- the target site may be allele-specific (e.g., a major or minor allele).
- homology arm is meant a portion of a donor polynucleotide that is responsible for targeting the donor polynucleotide to the genomic sequence to be edited in a cell.
- the donor polynucleotide typically comprises a 5' homology arm that hybridizes to a 5' genomic target sequence and a 3' homology arm that hybridizes to a 3' genomic target sequence flanking a nucleotide sequence comprising the intended edit to the genomic DNA.
- the homology arms are referred to herein as 5' and 3' (i.e., upstream and downstream) homology arms, which relates to the relative position of the homology arms to the nucleotide sequence comprising the intended edit within the donor polynucleotide.
- the 5' and 3' homology arms hybridize to regions within the target locus in the genomic DNA to be modified, which are referred to herein as the "5' target sequence” and "3' target sequence,” respectively.
- the nucleotide sequence comprising the intended edit is integrated into the genomic DNA by HDR or recombineering at the genomic target locus recognized (i.e., sufficiently complementary for hybridization) by the 5' and 3' homology arms.
- administering comprises transducing, transfecting, electroporating, translocating, fusing, phagocytosing, shooting or ballistic methods, etc., i.e., any means by which a nucleic acid can be transported across a cell membrane.
- microglia disorder is used herein to refer to any central nervous system (CNS) disorder, peripheral nervous system disorder, or other disorder associated with dysregulation of microglia (e.g., hyperactivation or hypoactivation) or impaired function of microglia.
- CNS central nervous system
- peripheral nervous system disorder or other disorder associated with dysregulation of microglia (e.g., hyperactivation or hypoactivation) or impaired function of microglia.
- Microglia disorders include, but are not limited to, chronic neuroinflammation, neuropathic pain, CNS- related injuries such as stroke, epilepsy, traumatic brain injury, and spinal cord injury, neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and Nasu- Hakola disease, glioma, meningitis, psychiatric diseases such as schizophrenia, autism spectrum disorder, and affective disorders, autonomic nerve dysfunction, cardiovascular disorders, such as hypertension, myocardial infarction, heart failure, cardiac ischemia/reperfusion injury, and ventricular arrhythmias, glaucoma, and infections, including infections of retroviruses such as human immunodeficiency virus (HIV) and human T lymphotropic virus type 1 , herpesviruses such as herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus, human herpesvirus 6,
- pathological pain any pain resulting from a pathology, such as from functional disturbances and/or pathological changes, lesions, burns and the like.
- pathological pain is “neuropathic pain” which is pain thought to initially result from nerve damage but extended or exacerbated by other mechanisms including glial cell activation.
- pathological pain examples include, but are not limited to, thermal or mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain, pain arising from irritable bowel or other internal organ disorders, endometriosis pain, phantom limb pain, complex regional pain syndromes, fibromyalgia, low back pain, fibrodysplasia ossificans progressiva (FOP) pain, cancer pain, pain arising from infection, inflammation or trauma to peripheral nerves or the central nervous system, multiple sclerosis pain, entrapment pain, and the like.
- thermal or mechanical hyperalgesia thermal or mechanical allodynia
- diabetic pain pain arising from irritable bowel or other internal organ disorders
- endometriosis pain arising from irritable bowel or other internal organ disorders
- endometriosis pain arising from irritable bowel or other internal organ disorders
- endometriosis pain arising from irritable bowel or other internal organ disorders
- endometriosis pain
- Hyperalgesia refers to an abnormally increased sensitivity to pain, including pain that results from excessive sensitivity to stimuli. Hyperalgesia can result from damage to nociceptors or nerves. Primary hyperalgesia refers to pain sensitivity that occurs in damaged tissues. Secondary hyperalgesia refers to pain sensitivity that occurs in undamaged tissue surrounding damaged tissue. Examples of hyperalgesia include, without limitation, thermal hyperalgesia (i.e., hypersensitivity to cold or heat) and opioid-induced hyperalgesia (e.g., hypersensitivity to pain as a result of long-term opioid use such as caused by treatment of chronic pain).
- thermal hyperalgesia i.e., hypersensitivity to cold or heat
- opioid-induced hyperalgesia e.g., hypersensitivity to pain as a result of long-term opioid use such as caused by treatment of chronic pain.
- “Hypalgesia” or “hypoalgesia” refers to decreased sensitivity to pain.
- Allodynia means pain that results from a normally non-painful, non-noxious stimulus to the skin or body surface.
- examples of allodynia include, but are not limited to, thermal (hot or cold) allodynia (e.g., pain from normally mild temperatures), tactile or mechanical allodynia (e.g., static mechanical allodynia (pain triggered by pressure), punctate mechanical allodynia (pain when touched), or dynamic mechanical allodynia (pain in response to stroking or brushing)), movement allodynia (pain triggered by normal movement of joints or muscles), and the like.
- thermal (hot or cold) allodynia e.g., pain from normally mild temperatures
- tactile or mechanical allodynia e.g., static mechanical allodynia (pain triggered by pressure), punctate mechanical allodynia (pain when touched), or dynamic mechanical allodynia (pain in response to stroking or brushing)
- Nociception is defined herein as pain sense.
- Nociceptor herein refers to a structure that mediates nociception. The nociception may be the result of a physical stimulus, such as, a mechanical, electrical, thermal, or a chemical stimulus. Nociceptors are present in virtually all tissues of the body.
- Analgesia is defined herein as the relief of pain without the loss of consciousness.
- An “analgesic” is an agent or drug useful for relieving pain, again, without the loss of consciousness.
- modulating pain refers to the modulation (e.g., inhibition or diminishment) of pain or the perception of pain in a given subject and includes absence from pain sensations as well as states of reduced or absent sensitivity to pain stimuli.
- altering the activity of a target neuron refers to changing the activity level of a cell function.
- altering the activity of a target neuron may include changing the membrane potential of a neuron, wherein the membrane potential of a neuron is important for its function (e.g., action potential firing).
- the activity of the neuron is altered such that the membrane potential is increased (e.g., hyperpolarized).
- the activity of the neuron is altered such that the membrane potential is decreased below a threshold potential, resulting in an action potential (e.g., depolarized).
- the firing rate of the neuron is altered.
- treatment used herein to generally refer to obtaining a desired pharmacologic and/or physiologic effect.
- the effect can be prophylactic in terms of completely or partially preventing a disease or symptom(s) thereof and/or may be therapeutic in terms of a partial or complete stabilization or cure for a disease and/or adverse effect attributable to the disease.
- treatment encompasses any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease and/or symptom(s) from occurring in a subject who may be predisposed to the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease and/or symptom(s), i.e., arresting their development; or (c) relieving the disease symptom(s), i.e., causing regression of the disease and/or symptom(s).
- Those in need of treatment include those already inflicted (e.g., those with a microglia disorder) as well as those in which prevention is desired (e.g., those with increased susceptibility or a genetic predisposition to developing a microglia disorder).
- a therapeutic treatment is one in which the subject is inflicted prior to administration and a prophylactic treatment is one in which the subject is not inflicted prior to administration.
- the subject has an increased likelihood of becoming inflicted or is suspected of being inflicted prior to treatment.
- the subject is suspected of having an increased likelihood of becoming inflicted.
- a chimeric animal is created by genetically modifying a non-human animal host embryo by deleting or inactivating a CSF1 R gene to create a microglia-deficient host.
- Stem cells having a functional CSF1 R gene are transplanted into the non-human animal host embryo and differentiated into microglia, which populate the central nervous system as the non-human animal host embryo grows.
- An adult chimeric animal having high microglia chimerism in the spinal cord is produced from the host embryo.
- the non-human animal can be any non-human animal known in the art that can be used in the methods as described herein.
- Such animals include, without limitation, non-human primates such as chimpanzees, gorillas, orangutans, and other apes and monkey species, cattle, sheep, pigs, goats, horses, deer, dogs, cats, ferrets, and rodents such as mice, rats, guinea pigs, hamsters, and rabbits.
- the genome of the non-human animal host embryo is genetically modified to delete or inactivate a CSF1 R gene (i.e. , gene knockout) using standard methods in the art.
- the non-human animal host embryo is genetically modified at the zygote stage.
- a site-specific nuclease is used to create a DNA break that can be repaired by homology directed repair (HDR) or non-homologous end joining (NHEJ) to produce a knockout of a CSF1 R gene.
- HDR homology directed repair
- NHEJ non-homologous end joining
- a donor polynucleotide is used comprising an intended edit sequence to be integrated into the genomic target locus.
- the donor polynucleotide is used, for example, to delete all or a portion of the CSF1 R gene or introduce a frameshift mutation.
- NHEJ the two DNA ends at the DNA break, produced by a site-specific nuclease, are ligated together imperfectly, resulting in incorporation of insertions or deletions of base pairs to create a frameshift mutation.
- a DNA break may be created by a site-specific nuclease, such as, but not limited to, a Cas nuclease (e.g., Cas9, Cpf1 , or C2c1 ), an engineered RNA-guided Fokl nuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector-based nuclease (TALEN), a restriction endonuclease, a meganuclease, a homing endonuclease, and the like.
- a site-specific nuclease such as, but not limited to, a Cas nuclease (e.g., Cas9, Cpf1 , or C2c1 ), an engineered RNA-guided Fokl nuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector-based nuclease (TALEN), a restriction endonu
- Genome Editing Using Site-Specific Nucleases: ZFNs, TALENs, and the CRISPR/Cas9 System (T. Yamamoto ed., Springer, 2015); Genome Editing: The Next Step in Gene Therapy (Advances in Experimental Medicine and Biology, T. Cathomen, M. Hirsch, and M. Porteus eds., Springer, 2016); Aachen Press Genome Editing (CreateSpace Independent Publishing Platform, 2015); herein incorporated by reference.
- genome modification is performed using HDR with a donor polynucleotide comprising a sequence comprising an intended genome edit flanked by a pair of homology arms responsible for targeting the donor polynucleotide to the target locus to be edited in a cell.
- the donor polynucleotide typically comprises a 5' homology arm that hybridizes to a 5' genomic target sequence and a 3' homology arm that hybridizes to a 3' genomic target sequence.
- the homology arms are referred to herein as 5' and 3' (i.e.
- upstream and downstream homology arms which relates to the relative position of the homology arms to the nucleotide sequence comprising the intended edit within the donor polynucleotide.
- the 5' and 3' homology arms hybridize to regions within the target locus in the genomic DNA to be modified, which are referred to herein as the "5' target sequence” and "3' target sequence,” respectively.
- the homology arm must be sufficiently complementary for hybridization to the target sequence to mediate homologous recombination between the donor polynucleotide and genomic DNA at the target locus.
- a homology arm may comprise a nucleotide sequence having at least about 80-100% sequence identity to the corresponding genomic target sequence, including any percent identity within this range, such as at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto, wherein the nucleotide sequence comprising the intended edit is integrated into the genomic DNA by HDR at the genomic target locus recognized (i.e., sufficiently complementary for hybridization) by the 5' and 3' homology arms.
- the corresponding homologous nucleotide sequences in the genomic target sequence flank a specific site for cleavage and/or a specific site for introducing the intended edit.
- the distance between the specific cleavage site and the homologous nucleotide sequences can be several hundred nucleotides. In some embodiments, the distance between a homology arm and the cleavage site is 200 nucleotides or less (e.g., 0, 10, 20, 30, 50, 75, 100, 125, 150, 175, and 200 nucleotides).
- the donor polynucleotide is substantially identical to the target genomic sequence, across its entire length except for the sequence changes to be introduced to a portion of the genome that encompasses both the specific cleavage site and the portions of the genomic target sequence to be altered.
- a homology arm can be of any length, e.g., 10 nucleotides or more, 50 nucleotides or more, 100 nucleotides or more, 250 nucleotides or more, 300 nucleotides or more, 350 nucleotides or more, 400 nucleotides or more, 450 nucleotides or more, 500 nucleotides or more, 1000 nucleotides (1 kb) or more, 5000 nucleotides (5 kb) or more, 10000 nucleotides (10 kb) or more, etc.
- the 5' and 3' homology arms are substantially equal in length to one another, e.g., one may be 30% shorter or less than the other homology arm, 20% shorter or less than the other homology arm, 10% shorter or less than the other homology arm, 5% shorter or less than the other homology arm, 2% shorter or less than the other homology arm, or only a few nucleotides less than the other homology arm.
- the 5' and 3' homology arms are substantially different in length from one another, e.g., one may be 40% shorter or more, 50% shorter or more, sometimes 60% shorter or more, 70% shorter or more, 80% shorter or more, 90% shorter or more, or 95% shorter or more than the other homology arm.
- the donor polynucleotide is used in combination with a site-specific nuclease.
- the site-specific nuclease is an RNA-guided nuclease, which is targeted to a particular genomic sequence (i.e., genomic target sequence to be modified) by a guide RNA (gRNA).
- gRNA guide RNA
- a target-specific guide RNA comprises a nucleotide sequence that is complementary to a genomic target sequence, and thereby mediates binding of the nuclease-gRNA complex by hybridization at the target site.
- the gRNA can be designed with a sequence complementary to a target sequence in a gene of interest.
- a CRISPR system is used to knockdown or knockout a CSF1 R gene in the non-human animal host embryo.
- the RNA-guided nuclease used for genome modification is a CRISPR system Cas nuclease. Any RNA-guided Cas nuclease capable of catalyzing site-directed cleavage of DNA to allow integration of donor polynucleotides by the HDR mechanism can be used in genome editing, including CRISPR system type I, type II, or type III Cas nucleases.
- Cas proteins include Cas1 , Cas1 B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1 , Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Casl Od, Cas12a (Cpf1 ), Cas12b (C2c1 ), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), CasF, CasG, CasH, Csy1 , Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1 , Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm
- a type II CRISPR system Cas9 endonuclease is used.
- Cas9 nucleases from any species, or biologically active fragments, variants, analogs, or derivatives thereof that retain Cas9 endonuclease activity i.e., catalyze site-directed cleavage of DNA to generate double-strand breaks
- the Cas9 need not be physically derived from an organism, but may be synthetically or recombinantly produced.
- Cas9 sequences from a number of bacterial species are well known in the art and listed in the National Center for Biotechnology Information (NCBI) database.
- NCBI National Center for Biotechnology Information
- sequences or a variant thereof comprising a sequence having at least about 70-100% sequence identity thereto, including any percent identity within this range, such as 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used for genome editing, as described herein. See also Fonfara et al. (2014) Nucleic Acids Res. 42(4):2577-90; Kapitonov et al. (2015) J. Bacteriol.
- the CRISPR-Cas system naturally occurs in bacteria and archaea where it plays a role in RNA-mediated adaptive immunity against foreign DNA.
- the bacterial type II CRISPR system uses the endonuclease, Cas9, which forms a complex with a guide RNA (gRNA) that specifically hybridizes to a complementary genomic target sequence, where the Cas9 endonuclease catalyzes cleavage to produce a double-stranded break.
- gRNA guide RNA
- Targeting of Cas9 typically further relies on the presence of a 5' protospacer-adjacent motif (PAM) in the DNA at or near the gRNA-binding site.
- PAM 5' protospacer-adjacent motif
- the genomic target site will typically comprise a nucleotide sequence that is complementary to the gRNA, and may further comprise a protospacer adjacent motif (PAM).
- the target site comprises 20-30 base pairs in addition to a 3 base pair PAM.
- the first nucleotide of a PAM can be any nucleotide, while the two other nucleotides will depend on the specific Cas9 protein that is chosen.
- Exemplary PAM sequences are known to those of skill in the art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide.
- the allele targeted by a gRNA comprises a mutation that creates a PAM within the allele, wherein the PAM promotes binding of the Cas9- gRNA complex to the allele.
- the gRNA is 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, or 19-21 nucleotides in length, or any length between the stated ranges, including, for example, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, or 35 nucleotides in length.
- the guide RNA may be a single guide RNA comprising crRNA and tracrRNA sequences in a single RNA molecule, or the guide RNA may comprise two RNA molecules with crRNA and tracrRNA sequences residing in separate RNA molecules.
- Cpf1 the CRISPR nuclease from Prevotella and Francisella 1
- Cas12a the CRISPR nuclease from Prevotella and Francisella 1
- Cpf1 is another class II CRISPR/Cas system RNA-guided nuclease with similarities to Cas9 and may be used analogously. Unlike Cas9, Cpf1 does not require a tracrRNA and only depends on a crRNA in its guide RNA, which provides the advantage that shorter guide RNAs can be used with Cpf1 for targeting than Cas9.
- Cpf 1 is capable of cleaving either DNA or RNA.
- the PAM sites recognized by Cpf 1 have the sequences 5'-YTN-3' (where "Y” is a pyrimidine and “N” is any nucleobase) or 5'-TTN-3', in contrast to the G-rich PAM site recognized by Cas9.
- Cpf1 cleavage of DNA produces double-stranded breaks with a sticky- ends having a 4 or 5 nucleotide overhang.
- Cpf 1 see, e.g., Ledford et al. (2015) Nature. 526 (7571 ) :17-17, Zetsche et al. (2015) Cell. 163 (3):759-771 , Murovec et al. (2017) Plant BiotechnoL J. 15(8):917-926, Zhang et al. (2017) Front. Plant Sci. 8:177, Fernandes et al. (2016) Postepy Biochem. 62(3):315-326; herein incorporated by reference.
- Cas12b (C2c1) is another class II CRISPR/Cas system RNA-guided nuclease that may be used.
- C2c1 similarly to Cas9, depends on both a crRNA and tracrRNA for guidance to target sites.
- For a description of Cas12b see, e.g., Shmakov et al. (2015) Mol Cell. 60(3):385-397, Zhang et al. (2017) Front Plant Sci. 8:177; herein incorporated by reference.
- RNA-guided Fokl nucleases comprise fusions of inactive Cas9 (dCas9) and the Fokl endonuclease (Fokl-dCas9), wherein the dCas9 portion confers guide RNA-dependent targeting on Fokl.
- dCas9 inactive Cas9
- Fokl-dCas9 Fokl endonuclease
- engineered RNA-guided Fokl nucleases see, e.g., Havlicek et al. (2017) Mol. Ther. 25(2):342-355, Pan et al. (2016) Sci Rep. 6:35794, Tsai et al. (2014) Nat BiotechnoL 32(6):569-576; herein incorporated by reference.
- RNA-guided nuclease can be provided in the form of a protein, such as the nuclease complexed with a gRNA, or provided by a nucleic acid encoding the RNA-guided nuclease, such as an RNA (e.g., messenger RNA) or DNA (expression vector).
- RNA e.g., messenger RNA
- DNA expression vector
- the RNA- guided nuclease and the gRNA are both provided by vectors. Both can be expressed by a single vector or separately on different vectors.
- the vector(s) encoding the RNA-guided nuclease an gRNA may be included in a CRISPR expression system to target a CSF1 R gene in the nonhuman animal host embryo.
- Codon usage may be optimized to improve production of an RNA-guided nuclease in a particular cell or organism.
- a nucleic acid encoding an RNA-guided nuclease or reverse transcriptase can be modified to substitute codons having a higher frequency of usage in a human cell, a non-human cell, a mammalian cell, a rodent cell, a mouse cell, a rat cell, or any other host cell of interest, as compared to the naturally occurring polynucleotide sequence.
- CRISPR interference is used to repress gene expression of a CSF1 R gene in the non-human animal host embryo.
- CRISPRi is performed with a complex of a catalytically inactive Cas9 (dCas9) with a guide RNA that targets the gene of interest.
- An engineered nuclease-deactivated Cas9 is used to allow sequence-specific targeting without cleavage.
- Nuclease-deactivated forms of Cas9 may be engineered by mutating catalytic residues at the active site of Cas9 to destroy nuclease activity. Any such nuclease deficient Cas9 protein from any species may be used as long as the engineered dCas9 retains gRNA-mediated sequence-specific targeting.
- the nuclease activity of Cas9 from Streptococcus pyogenes can be deactivated by introducing two mutations (D10A and H841 A) in the RuvC1 and HNH nuclease domains.
- Other engineered dCas9 proteins may be produced by similarly mutating the corresponding residues in other bacterial Cas9 isoforms.
- the dCas9 protein can be designed to target a gene of interest by altering its guide RNA sequence.
- a target-specific single guide RNA comprises a nucleotide sequence that is complementary to a target site, and thereby mediates binding of the dCas9-sgRNA complex by hybridization at the target site.
- CRISPRi can be used to sterically repress transcription by blocking either transcriptional initiation or elongation by designing a sgRNA with a sequence complementary to a promoter or exonic sequence.
- the sgRNA may be complementary to the non-template strand or the template strand, but preferably is complementary to the non-template strand to more strongly repress transcription.
- the target site will typically comprise a nucleotide sequence that is complementary to the sgRNA, and may further comprise a protospacer adjacent motif (PAM).
- the target site comprises 20-30 base pairs in addition to a 3 base pair PAM.
- the first nucleotide of a PAM can be any nucleotide, while the two other nucleotides will depend on the specific Cas9 protein that is chosen.
- Exemplary PAM sequences are known to those of skill in the art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide.
- the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15- 25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, and any length between the stated ranges, including, for example, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.
- the sgRNAs are readily synthesized by standard techniques, e.g., solid phase synthesis via phosphoramidite chemistry, as disclosed in U.S. Patent Nos. 4,458,066 and 4,415,732, incorporated herein by reference; Beaucage et aL, Tetrahedron (1992) 48:2223-2311 ; and Applied Biosystems User Bulletin No. 13 (1 April 1987).
- Other chemical synthesis methods include, for example, the phosphotriester method described by Narang et aL, Meth. Enzymol. (1979) 68:90 and the phosphodiester method disclosed by Brown et aL, Meth. Enzymol. (1979) 68:109.
- the dCas9 is fused to a transcriptional repressor domain capable of further repressing transcription of the gene of interest, e.g., by inducing heterochromatinization.
- a Kruppel associated box KRAB
- KRAB Kruppel associated box
- dCas9 can be used to introduce epigenetic changes that reduce expression of a CSF1 R gene by fusion of dCas9 to an epigenetic modifier such as a chromatin-modifying epigenetic enzyme.
- the promoter for the gene of interest can be silenced, for example, by methylation or acetylation (e.g., histone H3 lysine 9 [H3K9] methylation, histone H3 lysine 27 [H3K27] methylation, and/or DNA methylation).
- fusion of dCas9 to a DNA methyltransferase such as DNA methyltransferase 3 alpha (DNMT3A) or a chimeric Dnmt3a/Dnmt3L methyltransferase (DNMT3A3L) allows targeted DNA methylation.
- Fusion of dCas9 to histone demethylase LSD1 allows targeted histone demethylation (see, e.g., Liu et aL (2016) Cell 167(1 ):233-247, Lo et al. (2017) FWOORes. 6. pii: F1000 Faculty Rev-747, and Stepper et al. (2017) Nucleic Acids Res. 45(4):1703-1713; herein incorporated by reference).
- an RNA-targeting CRISPR-Cas13 system is used to perform RNA interference to reduce expression of a CSF1 R gene.
- Members of the Cas13 family are RNA- guided RNases containing two HEPN domains having RNase activity.
- Cas13a (C2c2), Cas13b (C2c6), and Cas13d can be used for RNA knockdown.
- Cas13 proteins can be made to target and cleave transcribed RNA using a gRNA with complementarity to the target transcript sequence.
- the gRNA is typically about 64 nucleotides in length with a short hairpin crRNA and a 28-30 nucleotide spacer that is complementary to the target site on the RNA transcript.
- Cas13 recognition and cleavage of a target transcript results in degradation of the transcript as well as nonspecific degradation of any nearby transcripts. See, e.g., Abudayyeh et al. (2017) Nature 550:280-284, Hameed et al. (2019) Microb. Pathog. 133:103551 , Wang et al. (2019) Biotechnol Adv. 37(5):708-729, Aman et al. (2016) Viruses 10(12). pii: E732, and Zhang et al. (2016) Cell 175(1 ):212-223; herein incorporated by reference.
- the stem cells can be introduced into the animal host embryo at the blastocyst or morula stage.
- transplantation of the stem cells is performed in utero to a conceptus or to an embryo in in vitro culture.
- stem cells can be injected into a blastocyst cavity near the inner cell mass or aggregated with morula-stage embryo cells.
- at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 stem cells or more are introduced into the animal host embryo.
- 5-10 stem cells are introduced into the animal host embryo, including any number of stem cells within this range such as 5, 6, 7, 8, 9, or 10 stem cells.
- the stem cells transplanted into the animal host embryo may be any type of stem cell, including, without limitation, embryonic stem cells, adult stem cells, or induced pluripotent stem cells (IPSCs).
- the stem cells are mammalian stem cells.
- the mammalian stem cells are human stem cells.
- IPSCs can be generated by reprogramming somatic cells into pluripotent stem cells. Somatic cells can be induced into forming pluripotent stem cells, for example, by treating them with reprograming factors such as Yamanaka factors, including but not limited to, OCT3, OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28 (see, e.g., Takahashi et al. (2007) Cell. 131 (5):861 - 872; herein incorporated by reference in its entirety).
- reprograming factors such as Yamanaka factors, including but not limited to, OCT3, OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28 (see, e.g., Takahashi et al. (2007) Cell. 131 (5):861 - 872; herein incorporated by reference in its entirety).
- somatic cells that may be converted into IPSCs include, without limitation, peripheral blood mononuclear cells, fibroblasts, keratin ocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells, adipose derived stem cells, leukocytes, hematopoietic stem cells, bone marrow cells, and hepatocytes.
- Somatic cells are contacted with reprogramming factors in a combination and quantity sufficient to reprogram the cells to pluripotency.
- Reprogramming factors may be provided to the somatic cells individually or as a single composition, that is, as a premixed composition, of reprogramming factors. In some embodiments the reprogramming factors are provided as a plurality of coding sequences on a vector.
- Methods for "introducing a cell reprogramming factor into somatic cells are not limited in particular, and known procedures can be selected and used as appropriate.
- methods include ones using protein introducing reagents, fusion proteins with protein transfer domains (PTDs), electroporation, and microinjection.
- a nucleic acid(s), such as cDNA(s), encoding the cell reprogramming factor can be inserted in an appropriate expression vector comprising a promoter that functions in somatic cells, which then can be introduced into somatic cells by procedures such as infection, lipofection, liposomes, electroporation, calcium phosphate coprecipitation, DEAE-dextran, microinjection, and electroporation.
- an "expression vector” examples include viral vectors, such as lentiviruses, retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses; and expression plasmids for animal cells.
- viral vectors such as lentiviruses, retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses
- expression plasmids for animal cells For example, retroviral or Sendai virus (SeV) vectors are commonly used to introduce a nucleic acid(s) encoding a cell reprogramming factor as described above into somatic cells.
- SeV Sendai virus
- a sample comprising somatic cells is obtained from the subject.
- the somatic cells may include, without limitation, peripheral blood mononuclear cells, fibroblasts, keratinocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells, adipose derived stem cells, leukocytes, hematopoietic stem cells, bone marrow cells, and hepatocytes, and other cell types capable of generating patient-derived IPSCs,
- the biological sample comprising somatic cells is typically whole blood, buffy coat, peripheral blood mononucleated cells (PBMCS), skin, fat, or a biopsy, but can be any sample from bodily fluids, tissue or cells that contain suitable somatic cells.
- a biological sample can be obtained from a subject by conventional techniques. For example, blood can be obtained by venipuncture, and solid tissue samples can be obtained by surgical techniques according to methods well known in the art.
- the stem cells that are transplanted into the non-human animal host embryo are adult stem cells.
- exemplary adult stem cells include, without limitation, mesenchymal stem cells (e.g., from placenta, adipose tissue, lung, bone marrow, or blood), hematopoietic stem cells, mammary stem cells, intestinal stem cells, endothelial stem cells, and neural stem cells.
- the stem cells or somatic cells from which IPSCs are generated are preferably obtained from the mammalian subject that will be receiving the chimeric microglia transplant.
- the cells can be obtained directly from a donor, a culture of cells from a donor, or from established cell culture lines. Cells are preferably of the same immunological profile as the subject receiving the transplant.
- Adult stem cells and somatic cells can be obtained, for example, by biopsy from a close relative or matched donor.
- the stem cells express a functional or wild-type CSF1 R gene (i.e., the CSF1 R gene that is deficient in the non-human animal host embryo where the CSF1 R gene is deleted or inactivated).
- the stem cells are genetically modified to overexpress the CSF1 R gene.
- Overexpression of CSF1 R can be accomplished, for example, by cloning a nucleic acid encoding the colony-stimulating factor 1 receptor into an expression vector to create an expression cassette and transfecting the stem cells with the expression vector.
- NCBI National Center for Biotechnology Information
- Expression cassettes typically include control elements operably linked to the coding sequence, which allow for the expression of the gene in mammalian cells.
- typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV immediate early promoter, the mouse mammary tumor virus LTR promoter, the adenovirus major late promoter (Ad MLP), and the herpes simplex virus promoter, among others.
- Other nonviral promoters such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression.
- a promoter can be selected that overexpresses the CSF1 R gene.
- transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon.
- a sequence for optimization of initiation of translation located 5' to the coding sequence, is also present.
- transcription terminator/polyadenylation signals include those derived from SV40, as described in Sambrook et al., supra, as well as a bovine growth hormone terminator sequence.
- Enhancer elements may also be used herein to increase expression levels of the mammalian constructs. Examples include the SV40 early gene enhancer, as described in Dijkema et al., EMPO J. (1985) 4:761 , the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et aL, Proc. Natl. Acad. Sci. USA (1982b) 79:6777 and elements derived from human CMV, as described in Boshart et aL, Cell (1985) 41 :521 , such as elements included in the CMV intron A sequence.
- LTR long terminal repeat
- a number of viral based systems have been developed for gene transfer into mammalian cells. These include adenoviruses, retroviruses (y-retroviruses and lentiviruses), poxviruses, adeno-associated viruses, baculoviruses, and herpes simplex viruses (see e.g., Warnock et al. (201 1 ) Methods Mol. Biol. 737:1-25; Walther et al. (2000) Drugs 60(2):249-271 ; and Lundstrom (2003) Trends BiotechnoL 21 (3) :117-122; herein incorporated by reference).
- retroviruses provide a convenient platform for gene delivery systems. Selected sequences can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo.
- retroviral systems have been described (U.S. Pat. No. 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A. D. (1990) Human Gene Therapy 1 :5-14; Scarpa et al. (1991 ) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci.
- Lentiviruses are a class of retroviruses that are particularly useful for delivering polynucleotides to mammalian cells because they are able to infect both dividing and nondividing cells (see e.g., Lois et al (2002) Science 295:868-872; Durand et al. (201 1 ) Viruses 3(2):132-159; herein incorporated by reference).
- adenovirus vectors have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham, J. Virol. (1986) 57:267- 274; Bett et aL, J. Virol. (1993) 67:5911 -5921 ; Mittereder et aL, Human Gene Therapy (1994) 5:717-729; Seth et aL, J. Virol. (1994) 68:933-940; Barr et aL, Gene Therapy (1994) 1 :51-58; Berkner, K. L.
- AAV vector systems have been developed for gene delivery.
- AAV vectors can be readily constructed using techniques well known in the art. See, e.g., U.S. Pat. Nos. 5,173,414 and 5,139,941 ; International Publication Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et aL, Molec. Cell. Biol.
- Another vector system useful for delivering the polynucleotides encoding the colonystimulating factor 1 receptor is the enterically administered recombinant poxvirus vaccines described by Small, Jr., P. A., et al. (U.S. Pat. No. 5,676,950, issued Oct. 14, 1997, herein incorporated by reference).
- Additional viral vectors which will find use for delivering the nucleic acid molecules encoding the colony-stimulating factor 1 receptor include those derived from the pox family of viruses, including vaccinia virus and avian poxvirus.
- vaccinia virus recombinants expressing the colony-stimulating factor 1 receptor can be constructed as follows. The DNA encoding the colony-stimulating factor 1 receptor coding sequence is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia.
- TK thymidine kinase
- Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the coding sequences of interest into the viral genome.
- the resulting TK-recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.
- avipoxviruses such as the fowlpox and canarypox viruses
- Recombinant avipox viruses expressing immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species.
- the use of an avipox vector is particularly desirable in human and other mammalian species since members of the avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells.
- Methods for producing recombinant avipoxviruses are known in the art and employ genetic recombination, as described above with, respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.
- Molecular conjugate vectors such as the adenovirus chimeric vectors described in Michael et al., J. Biol. Chem. (1993) 268:6866-6869 and Wagner et al., Proc. Natl. Acad. Sci. USA (1992) 89:6099-6103, can also be used for gene delivery.
- Sindbis virus SIN
- Semliki Forest virus SSV
- Venezuelan Equine Encephalitis virus VEE
- Sindbis-virus derived vectors useful for the practice of the instant methods, see, Dubensky et al. (1996) J. Virol. 70:508-519; and International Publication Nos. WO 95/07995, WO 96/17072; as well as, Dubensky, Jr., T. W., et al., U.S. Pat. No.
- chimeric alphavirus vectors comprised of sequences derived from Sindbis virus and Venezuelan equine encephalitis virus. See, e.g., Perri et al. (2003) J. Virol. 77: 10394-10403 and International Publication Nos. WO 02/099035, WO 02/080982, WO 01/81609, and WO 00/61772; herein incorporated by reference in their entireties.
- a vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression of the coding sequences of interest (for example, a colonystimulating factor 1 receptor expression cassette) in a host cell.
- coding sequences of interest for example, a colonystimulating factor 1 receptor expression cassette
- cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays extraordinar specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide of interest, driven by a T7 promoter.
- the polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into protein by the host translational machinery.
- the method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al., Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.
- an amplification system can be used that will lead to high level expression following introduction into host cells.
- a T7 RNA polymerase promoter preceding the coding region for T7 RNA polymerase can be engineered. Translation of RNA derived from this template will generate T7 RNA polymerase which in turn will transcribe more template. Concomitantly, there will be a cDNA whose expression is under the control of the T7 promoter. Thus, some of the T7 RNA polymerase generated from translation of the amplification template RNA will lead to transcription of the desired gene.
- T7 RNA polymerase can be introduced into cells along with the template(s) to prime the transcription reaction.
- the polymerase can be introduced as a protein or on a plasmid encoding the RNA polymerase.
- the synthetic expression cassette of interest can also be delivered without a viral vector.
- the synthetic expression cassette can be packaged as DNA or RNA in liposomes prior to delivery to the subject or to cells derived therefrom.
- Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid.
- the ratio of condensed DNA to lipid preparation can vary but will generally be around 1 :1 (mg DNA:micromoles lipid), or more of lipid.
- Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations, with cationic liposomes particularly preferred.
- Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Feigner et aL, Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081 ); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192), in functional form.
- Cationic liposomes are readily available.
- N[1 -2,3-dioleyloxy)propyl]-N,N,N- triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Feigner et aL, Proc. NatL Acad. Sci. USA (1987) 84:7413- 7416).
- Other commercially available lipids include (DDAB/DOPE) and DOTAP/DOPE (Boerhinger).
- Other cationic liposomes can be prepared from readily available materials using techniques well known in the art.
- anionic and neutral liposomes are readily available, such as, from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials.
- Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others.
- DOPC dioleoylphosphatidyl choline
- DOPG dioleoylphosphatidyl glycerol
- DOPE dioleoylphoshatidyl ethanolamine
- the liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs).
- MLVs multilammelar vesicles
- SUVs small unilamellar vesicles
- LUVs large unilamellar vesicles
- the various liposome-nucleic acid complexes are prepared using methods known in the art. See, e.g., Straubinger et aL, in METHODS OF IMMUNOLOGY (1983), Vol. 101 , pp. 512-527; Szoka et aL, Proc. Natl. Acad. Sci. USA (1978) 75:4194-4198; Papahadjopoulos et aL, Biochim. Biophys.
- DNA and/or peptide(s) can also be delivered in cochleate lipid compositions similar to those described by Papahadjopoulos et aL, Biochem. Biophys. Acta (1975) 394:483-491. See, also, U.S. Pat. Nos. 4,663,161 and 4,871 ,488.
- the expression cassette of interest may also be encapsulated, adsorbed to, or associated with, particulate carriers.
- particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co- glycolides), known as PLG. See, e.g., Jeffery et aL, Pharm. Res. (1993) 10:362-368; McGee J. P., et aL, J MicroencapsuL 14(2):197-210, 1997; O'Hagan D. T., et aL, Vaccine 11 (2):149-54, 1993.
- particulate systems and polymers can be used for delivery of the nucleic acid of interest.
- polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules, are useful for transferring a nucleic acid of interest.
- DEAE dextran-mediated transfection, calcium phosphate precipitation or precipitation using other insoluble inorganic salts, such as strontium phosphate, aluminum silicates including bentonite and kaolin, chromic oxide, magnesium silicate, talc, and the like will find use with the present methods. See, e.g., Feigner, P.
- Peptoids Zuckerman, R. N., et aL, U.S. Pat. No. 5,831 ,005, issued Nov. 3, 1998, herein incorporated by reference
- biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering synthetic expression cassettes of the present invention.
- the particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun.”
- a gun powder discharge from a "gene gun” For a description of such techniques, and apparatuses useful therefore, see, e.g., U.S. Pat. Nos. 4,945,050; 5,036,006; 5,100,792; 5,179,022; 5,371 ,015; and 5,478,744.
- needle-less injection systems can be used (Davis, H. L., et al, Vaccine 12:1503- 1509, 1994; Bioject, Inc., Portland, Oreg.).
- Disease-relevant mutations can be introduced into the genome of the non-human animal or chimeric microglia using any method known in the art to produce a disease model.
- one or more disease-relevant mutations are introduced into the non-human animal embryo, the non-human animal produced from the embryo, the chimeric microglia, or a stem cell from which the chimeric microglia are derived.
- somatic cells, from which IPSCs are derived are obtained from normal individuals and subsequently genetically modified to introduce a disease-relevant mutation such as a mutation linked to a microglia disorder, then transplanted into a CSF1 R-deficient non-human animal host embryo to produce chimeric microglia comprising the disease-relevant mutation.
- the stem cells or somatic cells, from which IPSCs are derived are obtained from an individual comprising at least one allele encoding a mutation associated with a disease such as a mutation linked to a microglia disorder, wherein the IPSCs comprising the disease-relevant mutation are transplanted into a CSF1 R-deficient non-human animal host embryo to produce chimeric microglia comprising the disease-relevant mutation.
- the disease-relevant mutation is associated with a microglia disorder such as, but not limited to, chronic neuroinflammation, neuropathic pain, CNS-related injuries such as stroke, epilepsy, traumatic brain injury, and spinal cord injury, neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and Nasu-Hakola disease, glioma, meningitis, psychiatric diseases such as schizophrenia, autism spectrum disorder, and affective disorders, autonomic nerve dysfunction, cardiovascular disorders, such as hypertension, myocardial infarction, heart failure, cardiac ischemia/reperfusion injury, and ventricular arrhythmias, glaucoma, and infections, including infections of retroviruses such as human immunodeficiency virus (HIV) and human T lymphotropic virus type 1 , herpesviruses such as herpes simplex virus (HSV), cytomegal
- retroviruses such as
- the stem cells are genetically modified to introduce two or more disease-relevant mutations.
- disease-relevant mutations see, e.g., The Human Gene Mutation Database (HGMD®, hgmd.cf.ac.uk/ac/), MalaCards: The human disease database (malacards.org/), Gene4PD database (genemed.tech/gene4pd/home), Alz forum database (alzforum.org/mutations), MSgene database (msgene.org/), ALSOD: the Amyotrophic Lateral Sclerosis Online Database (alsod.org/), the AD/FTD Mutation database
- the disease-relevant mutation is in a gene selected from the group consisting of TREM2, TYROBP, CR3, CD33, CR1, SPI1, MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7, INPP5D, CD2AP, SOD1, GRN, PAX2, LRRK2, RIPK1, FMR1, DNMT3A, BIN1, TET2, AXL, APOE, CLEC7A, ITGAX, LGALS3, and CST7.
- TREM2 encodes the triggering receptor expressed on myeloid cells 2, a transmembrane receptor that modulates microglial activity and survival.
- TREM2 Nasu-Hakola disease
- AD Alzheimer’s disease
- FDD frontotemporal dementia
- PD Parkinson’s disease
- ALS amyotrophic lateral sclerosis
- TYROBP encodes a transmembrane adaptor protein.
- TYROBP may affect the function of various receptors expressed on the plasma membrane including TREM2, CD33, and CR3 and downstream signaling of SIRPi p.
- Mutations in TYROBP, CD33, and CR3 are linked to AD.
- the MS4A gene family encodes a class of tetraspanin proteins.
- MS4A gene family including MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7 have been implicated in AD.
- INPP5D encodes inositol polyphosphate-5-phosphatase D. Mutations in INPP5D have been linked to AD and cancer.
- a CRISPR/Cas system is used to make genetic changes to a gene of interest to produce a non-human animal useful for disease modeling and drug screening.
- a CRISPR/Cas system can be used to delete, inactivate, or mutate a gene, or eliminate or reduce gene expression or protein activity.
- Genome modification can be performed, for example, using homology directed repair (HDR) with a donor polynucleotide comprising a sequence comprising an intended genome edit flanked by a pair of homology arms responsible for targeting the donor polynucleotide to the target locus to be edited in a cell.
- HDR homology directed repair
- the donor polynucleotide typically comprises a 5' homology arm that hybridizes to a 5' genomic target sequence and a 3' homology arm that hybridizes to a 3' genomic target sequence.
- the homology arms are referred to herein as 5' and 3' (i.e., upstream and downstream) homology arms, which relates to the relative position of the homology arms to the nucleotide sequence comprising the intended edit within the donor polynucleotide.
- the 5' and 3' homology arms hybridize to regions within the target locus in the genomic DNA to be modified, which are referred to herein as the "5' target sequence" and "3' target sequence,” respectively.
- the homology arm must be sufficiently complementary for hybridization to the target sequence to mediate homologous recombination between the donor polynucleotide and genomic DNA at the target locus.
- a homology arm may comprise a nucleotide sequence having at least about 80-100% sequence identity to the corresponding genomic target sequence, including any percent identity within this range, such as at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto, wherein the nucleotide sequence comprising the intended edit is integrated into the genomic DNA by HDR at the genomic target locus recognized (i.e., sufficiently complementary for hybridization) by the 5' and 3' homology arms.
- the corresponding homologous nucleotide sequences in the genomic target sequence flank a specific site for cleavage and/or a specific site for introducing the intended edit.
- the distance between the specific cleavage site and the homologous nucleotide sequences can be several hundred nucleotides. In some embodiments, the distance between a homology arm and the cleavage site is 200 nucleotides or less (e.g., 0, 10, 20, 30, 50, 75, 100, 125, 150, 175, and 200 nucleotides).
- the donor polynucleotide is substantially identical to the target genomic sequence, across its entire length except for the sequence changes to be introduced to a portion of the genome that encompasses both the specific cleavage site and the portions of the genomic target sequence to be altered.
- the donor polynucleotide is used in combination with an RNA-guided nuclease, which is targeted to a particular genomic sequence (i.e., genomic target sequence to be modified) by a guide RNA (gRNA).
- gRNA guide RNA
- a target-specific guide RNA comprises a nucleotide sequence that is complementary to a genomic target sequence, and thereby mediates binding of the nuclease- gRNA complex by hybridization at the target site.
- the gRNA can be designed with a sequence complementary to a target sequence in a gene of interest where a disease-relevant mutation will be introduced.
- Chimeric microglia may be isolated from a non-human animal, produced as described herein, using methods known in the art.
- methods of isolating microglia typically involve dissociation of brain tissue by enzymatic treatment (e.g., treatment of brain tissue with dispase II, papain, and DNase I) followed by mechanical dissociation and cell separation by centrifugation with percoll gradients of various densities, fluorescence-activated cell sorting using microglia-specific surface markers, magnetic sorting, and/or immunopanning.
- enzymatic treatment e.g., treatment of brain tissue with dispase II, papain, and DNase I
- mechanical dissociation and cell separation by centrifugation with percoll gradients of various densities fluorescence-activated cell sorting using microglia-specific surface markers, magnetic sorting, and/or immunopanning.
- Microglia cell lines may be derived from such isolated cells, and immortalized using standard techniques, e.g., through use of viruses.
- the isolated microglia are useful for testing candidate agents to determine their effects on, e.g., morphology, gene expression, and/or activity of the microglia.
- isolated microglia comprising one or more disease-relevant mutations, which allow screening of candidate agents for their ability to treat a microglia disorder. Screening Assays
- a non-human animal comprising chimeric microglia, produced by the methods described herein, can be subjected to a plurality of candidate agents or other therapeutic intervention.
- candidate agents encompass numerous chemical classes, e.g., small organic compounds having a molecular weight of more than 50 daltons and less than about 10,000 daltons, less than about 5,000 daltons, or less than about 2,500 daltons.
- Test agents can comprise functional groups necessary for structural interaction with proteins, e.g., hydrogen bonding, and can include at least an amine, carbonyl, hydroxyl or carboxyl group, or at least two of the functional chemical groups.
- test agents can comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
- Test agents are also found among biomolecules including peptides, peptide fragments, receptor fragments, co-receptor fragments, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
- Test agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs. Moreover, screening may be directed to known pharmacologically active compounds and chemical analogs thereof, or to new agents with unknown properties such as those created through rational drug design.
- test agents are synthetic compounds.
- a number of techniques are available for the random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. See for example WO 94/24314, hereby expressly incorporated by reference, which discusses methods for generating new compounds, including random chemistry methods as well as enzymatic methods.
- test agents are provided as libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts that are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, including enzymatic modifications, to produce structural analogs.
- test agents are organic moieties.
- test agents are synthesized from a series of substrates that can be chemically modified. “Chemically modified” herein includes traditional chemical reactions as well as enzymatic reactions. These substrates generally include, but are not limited to, alkyl groups (including alkanes, alkenes, alkynes and heteroalkyl), aryl groups (including arenes and heteroaryl), alcohols, ethers, amines, aldehydes, ketones, acids, esters, amides, cyclic compounds, heterocyclic compounds (including purines, pyrimidines, benzodiazepins, beta-lactams, tetracylines, cephalosporins, and carbohydrates), steroids (including estrogens, androgens, cortisone, ecodysone, etc.), alkaloids (including ergots, vinca, curare, pyrollizdine, and mitomycines), organometallic compounds, hetero
- a test agent is assessed for any cytotoxic activity it may exhibit toward a living eukaryotic cell, using well-known assays, such as trypan blue dye exclusion, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide) assay, and the like. Agents that do not exhibit significant cytotoxic activity are considered candidate agents.
- the screening methods are used for identifying agents that promote the neuroprotective effects of microglia.
- candidate agents may be screened for their effects on phagocytosis and clearance of foreign material, toxins, pathogens, damaged cells, apoptotic cells, synaptic remnants, myelin debris, DNA fragments, neurofibrillary tangles, and/or plaques in the central nervous system.
- the screening methods are used for identifying inhibitors of microglial activation and/or the production of cytotoxic mediators by microglia which damage cells and cause neuronal cell death.
- a variety of assays may be used, and in many embodiments, a candidate agent will be tested in different assays to confirm the effects on microglia activity as well as efficacy in treating a microglia disorder.
- Activated microglia can be detected based on morphology, proliferation, expression of activation markers (e.g., IBA-1 , TLR4, CD14, CD16 CD32, CD86, macrophage receptor with collagenous structure (MARCO), or major histocompatibility complex II), secretion of effector molecules such as cytokines (e.g., interleukin (IL)-4, IL-5, IL-10, IL-13, IL-1 b, IL-6, IL-12, IL-17, IL-18, IL-23, transforming growth factor (TGF)-
- microglia Different morphological subtypes of microglia have been correlated with functional activity and extent of activation.
- the resting phenotype of microglia is characterized by a ramified morphology.
- the “activated” state is characterized by a larger cell body and shorter, thick processes.
- a “reactive state” is characterized by a small spherical morphology, rod-like morphology, or amoeboid-like morphology.
- Microglia may also exhibit a phagocytic “reactive phenotype” with processes containing pyknotic fragments (see, e.g., Fernandez-Arjona et al. (2017) Front. Cell Neurosci.
- Microglial activation may be evaluated, for example, using a Shell analysis (see, e.g., Catalin et al. (2013). Curr. Health Sci. J. 39 (Suppl 4):1 -5) or skeleton analysis (see, e.g., Morrison et al. (2013) J. Neuroinflammation 10(1 ):1 -20; herein incorporated by reference).
- Shell analysis see, e.g., Catalin et al. (2013). Curr. Health Sci. J. 39 (Suppl 4):1 -5)
- skeleton analysis see, e.g., Morrison et al. (2013) J. Neuroinflammation 10(1 ):1 -20; herein incorporated by reference.
- Morphology, phagocytosis, synaptic pruning, and scavenging activity of microglia can be monitored using microscopy techniques. Any suitable method known in the art may be used for imaging microglia including, without limitation, fluorescence microscopy, confocal microscopy, two-photon microscopy, multi-photon microscopy, light-field microscopy, expansion microscopy, light sheet microscopy, and electron microscopy.
- Activation of microglia leads to proliferation of microglia. Therefore, activation of a population of microglia can be detected by the increase in numbers of microglia.
- Cell proliferation can be detected and quantified, for example, by flow cytometry, using a cell counter, or staining of microglia with a fluorescent tracking dye, such as carboxyfluorescein succinimidyl ester (CFSE).
- CFSE carboxyfluorescein succinimidyl ester
- activation of microglia can also be detected by expression of activation markers.
- Transmembrane and surface proteins associated with activation of microglia include, but are not limited to, CD11 b, CD18, CR3, CD68, CD16, CD14, CD45, CA115, CX3CR1 , F4/80, and FCER1 G.
- Intracellular markers associated with activation include, but are not limited to, iNOS, I BA-1 , and ferritin.
- iNOS is an enzyme that produces NO, which promotes synthesis of IL- 6 and expression of the transcription factors IRF-1 and NF-KB that are involved in the microglia inflammatory response.
- IBA-1 is an intracellular actin-binding protein involved in reorganization of the microglial cytoskeleton and functions in promoting phagocytosis.
- Ferritin is involved in iron storage and is upregulated in activated microglia.
- Activation markers can be detected by standard methods, including, without limitation, immunohistochemistry, immunofluorescence, Western blot, or flow cytometry.
- changes in gene expression in response to a candidate agent can be detected, for example, by performing microarray analysis, RNA sequencing, or quantitative polymerase chain reaction.
- Microglia can also be characterized as having an anti-inflammatory phenotype, pro- inflammatory phenotype, or resting/surveilling phenotype which can be distinguished by detection of biomarkers (see, e.g., Xu et al. (2021) Neural Regen Res. 16(2): 270-280).
- Biomarkers of the anti-inflammatory phenotype include IL-13, TGF-
- Biomarkers of the pro-inflammatory phenotype include IL-6, IL-1 p, iNOS, TNF-a, and major histocompatibility complex II (MHCII).
- Biomarkers of the resting/surveilling phenotype include CD47, CXCR2, CX3CR1 , and CD200R1.
- Cytotoxicity of activated microglia involves secretion of hydrogen peroxide, nitric oxide, proteases, including matrix metallopeptidases, cathepsins, and tissue-type plasminogen activator, and cytokines and apoptotic factors such as TNF-a that induce apoptosis of target cells.
- Secretion of cytokines, chemokines, apoptotic factors, and proteases can be measured, for example, using a multiplexed enzyme-linked immunosorbent assay (ELISA). Surface markers can be detected, for example using standard immunohistochemistry and fluorescence microscopy techniques.
- Cytolysis can be assayed in vitro based on the release of compounds containing radioactive isotopes such as 51 Cr from radiolabeled target cells.
- a membrane- permeable live-cell labeling dye such as calcein acetoxymethyl ester of calcein (Calcein/AM) can be used to distinguish live cells from dead cells.
- Calcein/AM intracellular esterases cleave the acetoxymethyl (AM) ester group to produce a membrane-impermeable calcein fluorescent dye that is retained in live cells. Apoptotic and dead cells without intact cell membranes do not retain the calcein fluorescent dye.
- a lactate dehydrogenase (LDH) assay can also be used to evaluate cytotoxicity.
- LDH is a cytoplasmic enzyme, which is released into the extracellular space when the plasma membrane is damaged. Cytotoxicity is monitored by detecting LDH release from cells. See, e.g., Lieberman (2003) Nat Rev Immunol 3(5):361 -370, Neri et al. (2001 ) Clin Diagn Lab Immunol 8(6):1131 -1135, Smith et al. (201 1) PLoS One 6(11 ):e26908, Chan et al. (2013) Methods Mol Biol 979:65-70; herein incorporated by reference in their entireties. [00146] Flow cytometry can also be used to assess cell proliferation, activation, and cytotoxicity.
- the percentage of target cells that are live, apoptotic, or dead can be determined by staining target cells with viability dyes such that the live and dead cell populations can be distinguished based on differences in fluorescence.
- viability dyes such that the live and dead cell populations can be distinguished based on differences in fluorescence.
- Annexin V-FITC can be used to label target cells that are at an early stage of apoptosis.
- Propidium iodide can be used to label target cells that are at a late stage of apoptosis or dead.
- Lipophilic dyes, such as PKH67 and PKH26 can be used to label the cell membranes of target cells for measuring proliferation of microglia by flow cytometry. See, e.g., Zaritskaya et al.
- Microglia have been implicated in neuroinflammation and the pathogenesis of pain.
- Pro- inflammatory and anti-inflammatory cytokines secreted by microglia, regulate synaptic transmission and pain via neuron-glial interactions. Therefore, in certain embodiments, candidate agents are tested in a non-human animal to determine if an agent reduces neuroinflammation or relieves microglia-mediated pain.
- a candidate agent can be administered to a non- human animal experiencing neuroinflammation and/or pain to determine if the candidate agent is anti-inflammatory or analgesic.
- a variety of screening methods may be used for assessing whether an agent relieves pain and/or reduces pain affective-motivational behavior including sensory perception of pain, pain avoidance behavior, hyperalgesia, and allodynia.
- Exemplary screening methods include, without limitation, stimulus-evoked behavioral tests such as a mechanical withdrawal test, an electronic Von Frey test, a manual Von Frey test, a Randall-Selitto test, a Hargreaves test, a hot plate test, a cold plate test, a thermal probe test, an acetone evaporation test, cold plantar test, and a temperature preference test; and non-stimulus-evoked behavioral tests such as a grimace scale test, weight bearing and gait analysis, locomotive activity test (e.g., still, walking, trotting, running, distance traveled, velocity, eating/drinking and foraging behavior frequencies), and burrowing behavior test.
- locomotive activity test e.g., still, walking, trotting, running, distance traveled, velocity, eating/drinking and foraging behavior frequencies
- Pain induced by mechanical stimuli may include mechanical hyperalgesia or allodynia, which can be subdivided into dynamic (triggered by brushing), punctate (triggered by touch) and static (triggered by pressure) subtypes of hyperalgesia or allodynia.
- Testing for dynamic mechanical allodynia and hyperalgesia may include, for example, brushing the skin of a subject with a cotton ball or paintbrush. Punctate mechanical allodynia and hyperalgesia can be tested, for example, with a pinprick or von Frey filaments of varying forces (0.08-2940 mN).
- Static hyperalgesia can be tested, for example, by applying pressure to the skin or underlying tissue by pressing a finger or using a pressure algometer.
- Pain induced by heat or cold stimuli may include thermal hyperalgesia or allodynia.
- Thermal hyperalgesia or allodynia may be tested, for example, by applying a metal probe to the skin that increases or decreases in temperature to determine a threshold temperature at which pain is experienced. Pain induced by heat is typically experienced at temperatures of 42-48°C, and pain induced by cold is typically experienced at temperatures of 23.7-1 ,5°C.
- pain is inferred from “pain-like” behaviors, such as withdrawal from a nociceptive stimulus.
- An animal is considered to have allodynia if the animal withdraws from an innocuous stimulus that does not normally evoke a withdrawal response.
- An animal is considered to have hyperalgesia if an animal withdraws with an exaggerated response to a stimulus that does normally evoke a withdrawal response.
- Responses of animals to mechanical stimuli can be tested using a manual or electronic Von Frey test or the Randall Selitto test.
- Responses of animals to heat stimuli can be tested, for example, using the tail flick test, the Hargreaves test, a hot plate test, or a thermal probe test.
- Thermal hyperalgesia or allodynia can be tested in animals for example by using a temperature preference test. For example, an animal is allowed to choose between two adjacent areas maintained at different temperatures or a preferred position along a continuous temperature gradient (either in linear or circular form).
- a grimace scales test can be used to score the subjective intensity of pain based on facial expressions of a subject.
- facial features can be scored, including orbital tightening, nose/cheek bulge or flattening, ear position, and whisker position.
- Burrowing which is a self-motivated behavior, can also be used as a measure of spontaneous or nonstimulus evoked nociception in mice and rats. Gait and weight bearing of rodents also can be analyzed as an indicator of nociception.
- Other behavior that can be analyzed in test subjects include locomotive activity (still, walking, trotting, running), distance traveled, velocity, grooming, posture, eating/drinking and foraging. The frequencies of these behaviors in animal models of pain are compared to control states to determine if an agent alleviates pain or pain-motivated behavior.
- Methods of analysis at the single cell level are also of interest, such as live imaging (including confocal or light-sheet microscopy), single cell gene expression or single cell RNA sequencing, calcium imaging, immunocytochemistry, patch-clamping, flow cytometry and the like.
- live imaging including confocal or light-sheet microscopy
- single cell gene expression or single cell RNA sequencing single cell gene expression or single cell RNA sequencing
- calcium imaging including confocal or light-sheet microscopy
- immunocytochemistry including confocal or light-sheet microscopy
- patch-clamping single cell RNA sequencing
- flow cytometry flow cytometry
- chimeric microglia can be isolated from the non-human animal and used in screening assays.
- microglia in culture may be tested with one or a panel of cellular environments, where the cellular environment includes one or more of: exposure to a candidate agent of interest, contact with other cells such as neurons, electrical stimulation including alterations in ionicity, contact with pro-inflammatory or anti-inflammatory agents, contact with infectious agents, e.g. bacterial, viral, fungal, or parasitic infectious agents, and the like, and where cells may vary in genotype, in prior exposure to an environment of interest, in the dose of agent that is provided, etc.
- infectious agents e.g. bacterial, viral, fungal, or parasitic infectious agents, and the like
- infectious agents e.g. bacterial, viral, fungal, or parasitic infectious agents, and the like
- infectious agents e.g. bacterial, viral, fungal, or parasitic infectious agents, and the like
- infectious agents e.g. bacterial, viral, fungal, or parasitic infectious agents, and the
- chimeric microglia is typically performed in a sterile environment, for example, at 37°C. in an incubator containing a humidified 92-95% air/5-8% CO 2 atmosphere.
- Cell culture may be carried out in nutrient mixtures containing undefined biological fluids such as fetal calf serum, or media which is fully defined and serum free. The effect of the altering of the environment is assessed by monitoring multiple output parameters, including morphological, functional and genetic changes.
- the agents are conveniently added in solution, or readily soluble form, to the medium used in culturing the chimeric microglia.
- the agents may be added in a flow-through system, as a stream, intermittent or continuous, or alternatively, adding a bolus of the compound, singly or incrementally, to an otherwise static solution.
- a flow-through system two fluids are used, where one is a physiologically neutral solution, and the other is the same solution with the test compound added. The first fluid is passed over the multi-spheroid tissue, followed by the second.
- a bolus of the test compound is added to the volume of medium surrounding the multi-spheroid tissue.
- preferred agent formulations do not include additional components, such as preservatives, that may have a significant effect on the overall formulation.
- preferred formulations consist essentially of a biologically active compound and a physiologically acceptable carrier, e.g., water, ethanol, DMSO, etc.
- a physiologically acceptable carrier e.g., water, ethanol, DMSO, etc.
- the formulation may consist essentially of the compound itself.
- a plurality of assays may be run in parallel with different agent concentrations to obtain a differential response to the various concentrations.
- determining the effective concentration of an agent typically uses a range of concentrations resulting from 1 :10, or other log scale, dilutions.
- the concentrations may be further refined with a second series of dilutions, if necessary.
- one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection of the agent or at or below the concentration of agent that does not give a detectable change in the phenotype.
- Various methods can be utilized for quantifying the presence of selected parameters, in addition to the functional parameters described above.
- a convenient method is to label a molecule with a detectable moiety, which may be fluorescent, luminescent, radioactive, enzymatically active, etc., particularly a molecule specific for binding to the target analyte with high affinity.
- Fluorescent moieties are readily available for labeling virtually any biomolecule, structure, or cell type. Immunofluorescent moieties can be directed to bind not only to specific proteins but also specific conformations, cleavage products, or site modifications like phosphorylation.
- Individual peptides and proteins can be engineered to fluoresce, e.g., by expressing them as green fluorescent protein chimeras inside cells (for a review see Jones et al. (1999) Trends BiotechnoL 17(12):477-81 ).
- Cells can be genetically modified to provide fusions of an antibody to a fluorescent or bioluminescent protein.
- parameters may be measured using immunoassay techniques such as a radioimmunoassay (RIA) or enzyme linked immunosorbance assay (ELISA), homogeneous enzyme immunoassays, and related non-enzymatic techniques.
- RIA radioimmunoassay
- ELISA enzyme linked immunosorbance assay
- these techniques utilize specific antibodies as reporter molecules, which are particularly useful due to their high degree of specificity for attaching to a single molecular target.
- U.S. Pat. No. 4,568,649 describes ligand detection systems, which employ scintillation counting. These techniques are particularly useful for protein or modified protein parameters or epitopes, or carbohydrate determinants. Cell readouts for proteins and other cell determinants can be obtained using fluorescent or otherwise tagged reporter molecules.
- Cell based ELISA or related non-enzymatic or fluorescence-based methods enable measurement of cell surface parameters and secreted parameters.
- Capture ELISA and related non-enzymatic methods usually employ two specific antibodies or reporter molecules and are useful for measuring parameters in solution.
- Flow cytometry methods are useful for measuring cell surface and intracellular parameters, as well as shape change and granularity and for analyses of beads used as antibody- or probe-linked reagents. Readouts from such assays may be the mean fluorescence associated with individual fluorescent antibody-detected cell surface molecules or cytokines, or the average fluorescence intensity, the median fluorescence intensity, the variance in fluorescence intensity, or some relationship among these.
- Quantitative readouts of parameters may include baseline measurements in the absence of agents or a pre-defined genetic control condition and test measurements in the presence of a single or multiple agents or a genetic test condition. Furthermore, quantitative readouts of parameters may include long-term recordings and may therefore be used as a function of time (change of parameter value). Readouts may be acquired either spontaneously or in response to stimulation or perturbation of the microglia. The quantitative readouts of parameters may further include a single determined value, the mean or median values of parallel, subsequent or replicate measurements, the variance of the measurements, various normalizations, the cross-correlation between parallel measurements, etc. and every statistic used to a calculate a meaningful and informative factor.
- Co-cultures of microglia and neurons can be treated with pro-inflammatory agents to study neuroinflammation and microglia-mediated neurotoxicity in vitro, and to test candidate agents for neuroprotective effects and anti-inflammatory activity.
- the assays described herein are used to evaluate changes in function in response to optogenetic perturbation.
- optogenetics is used to induce cell-specific perturbations in the non-human animal test subject in vivo.
- optogenetics can be used to excite or inhibit one or more selected neurons of interest using light to test the effects on microglia activation and microglia-mediated neuroinflammation and neurotoxicity.
- the screening methods described above are applied to a nonhuman animal comprising one or more disease-relevant mutations such as mutations associated with a microglia disorder. Methods are also provided for determining the activity of a candidate agent on chimeric microglia, obtained from such a non-human animal. In some embodiments, the method comprises contacting microglia comprising at least one allele encoding a mutation associated with a microglia disorder with the candidate agent; and determining the effect of the agent on morphologic, genetic, or functional parameters.
- the disease-relevant mutation is in a gene selected from the group consisting of TREM2, TYROBP, CR3, CD33, CR1, SPI1, MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7, INPP5D, CD2AP, SOD1, GRN, PAX2, LRRK2, RIPK1, FMR1, DNMT3A, BIN1, TET2, AXL, APOE, CLEC7A, ITGAX, LGALS3, and CST7.
- TREM2 encodes the triggering receptor expressed on myeloid cells 2, a transmembrane receptor that modulates microglial activity and survival.
- TREM2 Nasu-Hakola disease
- AD Alzheimer’s disease
- FDD frontotemporal dementia
- PD Parkinson’s disease
- ALS amyotrophic lateral sclerosis
- TYROBP encodes a transmembrane adaptor protein.
- TYROBP may affect the function of various receptors expressed on the plasma membrane including TREM2, CD33, and CR3 and downstream signaling of SIRPi p.
- Mutations in TYROBP, CD33, and CR3 are linked to AD.
- the MS4A gene family encodes a class of tetraspanin proteins.
- MS4A gene family including MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7 have been implicated in AD.
- INPP5D encodes inositol polyphosphate-5-phosphatase D. Mutations in INPP5D have been linked to AD and cancer.
- Agents, identified by the screening methods described herein, as useful for treating a microglia disorder can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients.
- excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof.
- Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants.
- a carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient.
- carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like.
- the excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphat
- a composition of the invention can also include an antimicrobial agent for preventing or deterring microbial growth.
- antimicrobial agents suitable for the present invention include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and combinations thereof.
- An antioxidant can be present in the composition as well. Antioxidants are used to prevent oxidation, thereby preventing the deterioration of the agent, or other components of the preparation. Suitable antioxidants for use in the present invention include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.
- a surfactant can be present as an excipient.
- exemplary surfactants include: polysorbates, such as “Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (BASF, Mount Olive, New Jersey); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations.
- Acids or bases can be present as an excipient in the composition.
- acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof.
- Suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
- the amount of the agent (e.g., when contained in a drug delivery system) in the composition will vary depending on a number of factors but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial).
- a therapeutically effective dose can be determined experimentally by repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.
- the amount of any individual excipient in the composition will vary depending on the nature and function of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred.
- compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration.
- suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.
- solutions and suspensions are envisioned.
- compositions include those for intraneural, intracerebral, intrathecal, intraspinal, or localized delivery such as by stereotactic injection into the dorsal root ganglion (DRG).
- DRG dorsal root ganglion
- the pharmaceutical preparations herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use.
- the compositions comprising the agent are in unit dosage form, meaning an amount of a conjugate or composition of the invention appropriate for a single dose, in a premeasured or pre-packaged form.
- Chimeric microglia produced by a non-human animal donor according to the methods described herein can be used for transplantation.
- Healthy chimeric microglia may be used, for example, to replace or supplement dysfunctional microglia or a lack of microglia in a subject to restore neurological function.
- chimeric microglia may be tested to determine that the microglia are suitable for transplant. For example, chimeric microglia may be screened for normal morphology, phagocytic ability, expression of microglia-derived cytokines and chemokines, ability to prune synapses and neuronal connections, and ability to promote neurogenesis and angiogenesis.
- chimeric microglia are transplanted into a subject for treatment of a microglia disorder.
- Microglia disorders include, but are not limited to, chronic neuroinflammation, neuropathic pain, CNS-related injuries such as stroke, traumatic brain injury, and spinal cord injury, neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, frontotemporal dementia, amyotrophic lateral sclerosis, and Huntington disease, glioma, meningitis, psychiatric diseases such as schizophrenia, autism spectrum disorder, autonomic nerve dysfunction, cardiovascular disorders, such as hypertension, myocardial infarction, heart failure, cardiac ischemia/reperfusion injury, and ventricular arrhythmias, glaucoma, and infections, including infections of retroviruses such as human immunodeficiency virus (HIV) and human T lymphotropic virus type 1 , herpesviruses such as herpes simplex virus (HSV), cytomegalovirus (CM
- At least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or more of the cells in the chimeric microglia are derived from mammalian stem cells transplanted into the non-human animal host embryo.
- 70-100% of the cells in the chimeric organ or tissue are derived from mammalian stem cells transplanted into the non-human animal host embryo, including any percent within this range, such as 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100%.
- Chimeric microglia can be harvested from the chimeric donor and transplanted to a mammalian recipient.
- Microglia may be transplanted from the chimeric donor to a recipient such that the microglia are placed into the appropriate position in the central nervous system of the recipient’s body.
- the microglia are preferably from a living chimeric animal donor but, in some cases, may be from a deceased chimeric animal donor as long as the microglia remain viable.
- the mammalian recipient of the transplant will typically be human. However, the methods described herein may also find use in veterinarian applications such as for treatment of farm animals such as cattle, sheep, pigs, goats and horses and domestic mammals (e.g., pets) such as dogs and cats.
- an immune response may be mounted against the microglia after transplantation. During such episodes, the transplanted microglia may suffer diminished function or damage. The function and survival of the transplanted microglia may be improved by administration of an immunosuppressive agent.
- immunosuppressive agents include, without limitation, glucocorticoids, such as prednisone, dexamethasone, and hydrocortisone; calcineurin inhibitors such as tacrolimus and ciclosporin; mTOR inhibitors such as sirolimus, everolimus, and zotarolimus; cytostatics such as methotrexate, dactinomycin, anthracyclines, mitomycin C, bleomycin, and mithramycin; and antibodies such as anti-CD20, anti-CD25, and anti-CD3 monoclonal antibodies.
- glucocorticoids such as prednisone, dexamethasone, and hydrocortisone
- calcineurin inhibitors such as tacrolimus and ciclosporin
- mTOR inhibitors such as sirolimus, everolimus, and zotarolimus
- cytostatics such as methotrexate, dactinomycin, anthracyclines, mito
- Diagnosis of a rejection episode may utilize clinical data, markers for activation of immune function, markers for tissue damage, and the like. Histological signs include infiltrating T cells, perhaps accompanied by infiltrating eosinophils, plasma cells, and neutrophils, particularly in telltale ratios, structural compromise of tissue anatomy, varying by tissue type transplanted, and injury to blood vessels. Tissue biopsy is restricted, however, by sampling limitations and risks/complications of the invasive procedure. Cellular magnetic resonance imaging (MRI) of immune cells radiolabeled in vivo may provide noninvasive testing.
- MRI Cellular magnetic resonance imaging
- a method of producing a non-human animal comprising chimeric microglia comprising: a) genetically modifying a non-human animal host embryo by deleting or inactivating a CSF1 R gene; b) transplanting a stem cell comprising a functional CSF1 R gene into the non-human animal host embryo to produce a chimeric non-human animal host embryo; and c) producing a non-human animal from the chimeric non-human animal host embryo, wherein differentiation of the stem cell generates the chimeric microglia in the nervous system of the non-human animal.
- stem cell is an embryonic stem cell, an adult stem cell, or an induced pluripotent stem cell.
- stem cell is a mammalian stem cell.
- any one of aspects 1 -10 wherein said genetically modifying the non-human animal host embryo comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to delete or inactivate the CSF1 R gene.
- CRISPR clustered regularly interspaced short palindromic repeats
- TALEN transcription activator-like effector nuclease
- zinc-finger nuclease to delete or inactivate the CSF1 R gene.
- the CRISPR system comprises a single guide RNA (sgRNA) targeting the CSF1 R gene.
- sgRNA single guide RNA
- stem cell comprises a mutation linked to a microglia disorder.
- a non-human animal comprising chimeric microglia produced by the method of any one of aspects 1 -19.
- a method of screening a candidate agent comprising: administering the candidate agent to the non-human animal of aspect 20; and detecting an effect of the candidate agent on morphology, gene expression, or activity of the chimeric microglia, or any combination thereof.
- detecting the morphology of the chimeric microglia comprises detecting ramified, reactive, activated, amoeboid, or rod-like morphology.
- measuring the activity of the chimeric microglia comprises measuring secretion of cytokines, chemokines, NO, glucocorticoids, proteases, or glutamate, phagocytosis, synaptic pruning, or production of reactive oxygen species (ROS).
- ROS reactive oxygen species
- measuring the secretion by the chimeric microglia comprises detecting interleukin (IL)-4, IL-5, IL-10, IL-13, IL-10, IL-6, IL-12, IL-17, IL-18, IL-23, transforming growth factor (TGF)-0, tumor necrosis factor (TNF)-a, interferon (IFN)-y, CCL2, CX3CL1 , or CXCL10, or any combination thereof.
- TGF transforming growth factor
- TGF tumor necrosis factor
- IFN interferon
- measuring gene expression comprises performing microarray analysis, RNA sequencing, or quantitative polymerase chain reaction.
- measuring gene expression comprises detecting expression of a microglia activation marker.
- the genome of the non-human animal or the chimeric microglia comprises a mutation linked to a microglia disorder.
- the mutation is in a gene selected from the group consisting of TREM2, TYROBP, CR1, SPI1, MS4A4A, MS4A4E, MS4A6A, MS4A6E, ABCA7, CD33, INPP5D, CD2AP, SOD1, GRN, PAX2, LRRK2, RIPK1, FMR1, DNMT3A, BIN1, and TET2.
- a method of transplanting microglia into a mammalian recipient subject comprising transplanting chimeric microglia from the non-human animal of aspect 21 to the mammalian recipient subject.
- stem cell is an adult stem cell from the mammalian recipient subject.
- stem cell is an induced pluripotent stem cell derived from a somatic cell from the mammalian recipient subject.
- a non-human animal host embryo comprising: a) a genetically modified genome comprising a knockout of a CSF1 R gene; and b) transplanted stem cells having a wild-type CSF1 R gene, wherein a non-human animal can be produced from the chimeric non-human animal host embryo, wherein differentiation of the transplanted stem cells generates chimeric microglia in the nervous system of the non- human animal during development.
- 41 The non-human animal host embryo of aspect 40, wherein the non-human animal host embryo is a vertebrate.
- a method of screening a candidate agent comprising: contacting the isolated microglia of aspect 54 with the candidate; and detecting an effect of the candidate agent on morphology, gene expression, or activity of the chimeric microglia, or any combination thereof.
- detecting the morphology of the chimeric microglia comprises detecting ramified, reactive, activated, amoeboid, or rod-like morphology.
- measuring the activity of the chimeric microglia comprises measuring secretion of cytokines, chemokines, NO, glucocorticoids, proteases, or glutamate, phagocytosis, synaptic pruning, or production of reactive oxygen species (ROS).
- ROS reactive oxygen species
- measuring the secretion by the chimeric microglia comprises detecting interleukin (IL)-4, IL-5, IL-10, IL-13, IL-1 (3, IL-6, IL-12, IL-17, IL-18, IL-23, transforming growth factor (TGF)-p, tumor necrosis factor (TNF)-a, interferon (IFN)-y, CCL2, CX3CL1 , or CXCL10, or any combination thereof.
- IL interleukin
- TGF tumor necrosis factor
- IFN interferon
- measuring gene expression comprises performing microarray analysis, RNA sequencing, or quantitative polymerase chain reaction.
- measuring gene expression comprises detecting expression of a microglia activation marker.
- the activation marker is IBA-1 , TLR4, CD14, CD16 CD32, CD86, macrophage receptor with collagenous structure (MARCO), or major histocompatibility complex II.
- FIG. 4 A schematic of the protocol for blastocyst complementation is shown in FIG. 4.
- CRISPR was used to knockout the CSF1 R gene in mouse embryos at the 1 cell stage.
- donor mouse GFP-ESCs were injected into the embryos, which differentiated into microglia.
- Flow cytometry analysis showed that adult chimera had high microglia chimerism in the spinal cord (FIG. 5).
- the donor ESCs may be genetically modified to carry any desired mutation of interest, including mutations associated with microglia disorders. These results indicate that blastocyst microglia complementation may be used effectively to produce a nonhuman animal model carrying microglia mutations of interest for gene validation and therapeutic screening.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Environmental Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un animal non humain comprenant une microglie chimérique et des procédés de réalisation d'une complémentation de microglie de blastocyste pour produire un tel animal chimérique non humain sont divulgués. En particulier, les procédés divulgués peuvent être utilisés afin de produire un modèle animal non humain comportant des mutations de microglie d'intérêt pour la validation de gènes et le criblage thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263370743P | 2022-08-08 | 2022-08-08 | |
US63/370,743 | 2022-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024036106A1 true WO2024036106A1 (fr) | 2024-02-15 |
Family
ID=89852514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/071778 WO2024036106A1 (fr) | 2022-08-08 | 2023-08-07 | Complémentation de microglie embryonnaire pour manipulation in vivo de microglie et production d'un modèle animal non humain pour la validation de la fonction génique et le criblage thérapeutique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024036106A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140351965A1 (en) * | 2011-02-25 | 2014-11-27 | Recombinetics | Swine genetically modified with specificity for ldl-r knockout |
US20200315148A1 (en) * | 2013-01-29 | 2020-10-08 | The University Of Tokyo | Method for producing chimeric animal |
WO2021221879A1 (fr) * | 2020-05-01 | 2021-11-04 | Albert Einstein College Of Medicine | Compositions et procédés d'utilisation de microglie transplantée comme véhicule permettant l'administration étendue de cellules et d'autres agents biologiques au cerveau |
WO2021239308A1 (fr) * | 2020-05-27 | 2021-12-02 | Universität Zürich | Vecteurs viraux exprimant des protéines thérapeutiques spécifiquement dans les cellules myéloïdes et la microglie |
WO2022067105A1 (fr) * | 2020-09-25 | 2022-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Procédé de remplacement efficace de microglies |
-
2023
- 2023-08-07 WO PCT/US2023/071778 patent/WO2024036106A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140351965A1 (en) * | 2011-02-25 | 2014-11-27 | Recombinetics | Swine genetically modified with specificity for ldl-r knockout |
US20200315148A1 (en) * | 2013-01-29 | 2020-10-08 | The University Of Tokyo | Method for producing chimeric animal |
WO2021221879A1 (fr) * | 2020-05-01 | 2021-11-04 | Albert Einstein College Of Medicine | Compositions et procédés d'utilisation de microglie transplantée comme véhicule permettant l'administration étendue de cellules et d'autres agents biologiques au cerveau |
WO2021239308A1 (fr) * | 2020-05-27 | 2021-12-02 | Universität Zürich | Vecteurs viraux exprimant des protéines thérapeutiques spécifiquement dans les cellules myéloïdes et la microglie |
WO2022067105A1 (fr) * | 2020-09-25 | 2022-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Procédé de remplacement efficace de microglies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7209671B2 (ja) | ゲノムdnaを改変するための方法および組成物 | |
JP7263327B2 (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
Wiley et al. | Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases | |
US20190352602A1 (en) | Methods and Compositions for Producing Germ Cells from Bone Marrow Derived Germline Stem Cells | |
JP2021106611A (ja) | ヌクレアーゼ介在性遺伝子発現調節 | |
JP5866601B2 (ja) | 医薬組成物の製造方法 | |
US20160022737A1 (en) | Gene editing for hiv gene therapy | |
KR20200016954A (ko) | 전신 면역억제가 불필요한 동종 이식편 내성 | |
Rueda et al. | Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions | |
CN109476716A (zh) | 治疗线粒体障碍的方法 | |
US20230279440A1 (en) | Methods to genetically modify cells for delivery of therapeutic proteins | |
US20230212613A1 (en) | Methods for targeted insertion of exogenous sequences in cellular genomes | |
US20240060090A1 (en) | Genetically modified induced pluripotent stem cells and methods of use thereof | |
US12011488B2 (en) | Methods of treating mitochondrial disorders | |
EP3884055B1 (fr) | Construction de gènes suicides doubles et inductibles et son utilisation dans la thérapie génique | |
US20230272339A1 (en) | Compositions and methods for cellular component transfer therapy | |
US20230381225A1 (en) | Methods for the treatment of beta-thalassemia | |
WO2020206046A1 (fr) | Procédés et compositions pour thérapie cellulaire | |
WO2024036106A1 (fr) | Complémentation de microglie embryonnaire pour manipulation in vivo de microglie et production d'un modèle animal non humain pour la validation de la fonction génique et le criblage thérapeutique | |
KR102124236B1 (ko) | Park2 유전자 넉아웃 파킨슨 질환 모델용 돼지 및 이의 용도 | |
US20230180725A1 (en) | Production of Human Cells, Tissues, and Organs in a Growth Factor Receptor-Deficient Animal Host | |
EP4121120A2 (fr) | Méthodes de traitement de troubles mitochondriaux | |
Carmona et al. | OPEN ACCESS EDITED BY Eleonora lacono, University of Bologna, Italy | |
WO2023164573A1 (fr) | Cellules modifiées et leurs procédés d'utilisation | |
Microglia | Different Neurotropic Pathogens Elicit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23853454 Country of ref document: EP Kind code of ref document: A1 |